Key Points
- Noubar Afeyan, a Moderna director, sold 23,853 shares on December 11 at an average price of $29.48 for about $703,186, leaving him with 3,924 shares — an 85.87% reduction in his position.
- Moderna beat the recent quarter's estimates with EPS of ($0.51) and revenue of $1.02 billion, but revenue was down 45.4% year-over-year and the company reported a negative net margin (-139.61%), while analysts expect about -9.61 EPS for the current fiscal year.
- Analyst sentiment is mixed: the stock has an average rating of "Reduce" and an average price target of $29.21, with 2 Buys, 13 Holds and 5 Sells; the shares trade near $29.92 and the company has a market cap of $11.69 billion.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares of the company's stock, valued at approximately $115,679.52. The trade was a 85.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Moderna Price Performance
Moderna stock opened at $29.92 on Tuesday. The stock's 50 day moving average is $26.09 and its 200 day moving average is $27.08. Moderna, Inc. has a one year low of $22.28 and a one year high of $48.92. The firm has a market cap of $11.69 billion, a P/E ratio of -3.71 and a beta of 1.11.
Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company's revenue was down 45.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 EPS. Equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of Moderna in a report on Monday, October 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Moderna in a research note on Wednesday, October 8th. Bank of America decreased their target price on Moderna from $24.00 to $21.00 and set an "underperform" rating for the company in a research note on Monday, November 10th. UBS Group reiterated a "buy" rating on shares of Moderna in a report on Friday, November 21st. Finally, Piper Sandler restated an "overweight" rating on shares of Moderna in a report on Monday, December 1st. Two investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and an average price target of $29.21.
Read Our Latest Research Report on Moderna
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in MRNA. Allworth Financial LP boosted its holdings in Moderna by 21.0% in the third quarter. Allworth Financial LP now owns 4,629 shares of the company's stock worth $120,000 after acquiring an additional 804 shares in the last quarter. IFP Advisors Inc raised its position in shares of Moderna by 1,175.5% during the third quarter. IFP Advisors Inc now owns 5,880 shares of the company's stock worth $152,000 after purchasing an additional 5,419 shares during the period. Swiss Life Asset Management Ltd lifted its holdings in shares of Moderna by 34.4% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 21,558 shares of the company's stock worth $557,000 after purchasing an additional 5,523 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Moderna in the 3rd quarter valued at $913,000. Finally, Centaurus Financial Inc. grew its position in Moderna by 162.0% in the 3rd quarter. Centaurus Financial Inc. now owns 16,184 shares of the company's stock valued at $418,000 after purchasing an additional 10,007 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
